CCM2

Across TCGA pan-cancer cohorts, CCM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCM2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CCM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where CCM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	28	view →
UCEC	OS	Median	III,IV	0.298	1.000	.001	26	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	22	view →
HNSC	OS	Median	II,III,IV	0.992	0.935	.028	4	view →
LUAD	OS	Tertile	All	0.597	0.914	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCM2–CCRCC (DFS)

Open the CCRCC breakdown →